[HTML][HTML] Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
NS Callander, R Silbermann, JL Kaufman… - Blood Cancer …, 2024 - nature.com
In the MASTER study (NCT03224507), daratumumab+ carfilzomib/lenalidomide/
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
[HTML][HTML] Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
NS Callander, R Silbermann, JL Kaufman… - Blood Cancer …, 2024 - ncbi.nlm.nih.gov
Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor
[1-4] and immunomodulatory [5-7] mechanism of action, demonstrating greater cytotoxicity …
[1-4] and immunomodulatory [5-7] mechanism of action, demonstrating greater cytotoxicity …
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
N Callander, R Silbermann, J Kaufman… - Blood Cancer …, 2024 - europepmc.org
In the MASTER study (NCT03224507), daratumumab+ carfilzomib/lenalidomide/
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
NS Callander, R Silbermann… - Blood Cancer …, 2024 - utsouthwestern.elsevierpure.com
In the MASTER study (NCT03224507), daratumumab+ carfilzomib/lenalidomide/
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
NS Callander, R Silbermann, JL Kaufman… - Blood Cancer …, 2024 - search.ebscohost.com
In the MASTER study (NCT03224507), daratumumab+ carfilzomib/lenalidomide/
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
NS Callander, R Silbermann… - Blood cancer …, 2024 - pubmed.ncbi.nlm.nih.gov
In the MASTER study (NCT03224507), daratumumab+ carfilzomib/lenalidomide/
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
N Callander, R Silbermann, J Kaufman… - Blood Cancer …, 2024 - escholarship.org
In the MASTER study (NCT03224507), daratumumab+ carfilzomib/lenalidomide/
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
NS Callander, R Silbermann, JL Kaufman… - Blood Cancer …, 2024 - europepmc.org
In the MASTER study (NCT03224507), daratumumab+ carfilzomib/lenalidomide/
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …